Summary A new, simple and sensitive low pH ELISA method has been developed to measure serum levels of tumour associated antigens detectable by monoclonal antibodies HMFG1 and HMFG2. We examined sera from healthy controls, patients with neoplastic and non-neoplastic conditions of breast, liver and gastrointestinal tract. The majority of patients with metastatic breast cancer had elevated serum antigens (69% HMFG1, 72% HMFG2) compared to healthy controls (6.3% HMFG1, 3.0% HMFG2) or patients with benign breast disease (17% HNFG1, 4% HMFG2). There was no discrimination using these assays between patients with neoplastic and non-neoplastic conditions of liver and gastrointestinal tract. This new method promises to be of value in the assessment and management of patients with breast cancer.
In the minority of neoplasms, serum tumour markers can sensitively predict the presence of disease and can help to monitor the effects of treatment. The fl-subunit of human chorionic gonadotrophic (HCG) and a-fetoprotein (AFP) in germ cell tumours (Lange et al., 1976) , placental alkaline phosphatase (PLAP) in seminoma of testes (Epenetos et al., 1985) , and CA125 in epithelial ovarian cancer (Bast, et al., 1983) ), are examples of clinically useful tumour markers. Although elevated serum levels of several markers have been reported in patients with breast cancer the sensitivity and specificity of detection have been inadequate for early diagnosis and monitoring therapy (Burchell et al., 1984; Ceriani et al., 1982; Coombes et al., 1985; Cove et al., 1979; Goodall et al., 1985; Lamoureaux et al., 1982; Wang et al., 1984; Waalkes et al., 1978) .
In this report we describe a new, simple and sensitive method that measures tumour associated antigens detected by monoclonal antibodies HMFG1 and HMFG2. Serum levels of these antigens were found to be elevated in the majority of patients with breast cancer but only in a few cases of patients with benign breast disease of healthy blood donors. 
Materials and methods
Monoclonal antibodies HMFG1, HMFG2: These mouse IgGI antibodies were raised against delipidated preparation of the human milk fat globule. The mouse used for the development of HMFG2 also received cultured milk epithelial cells Arklie et al., 1981; Burchell et al., 1983 (Feller et al., 1985) . HMFGI and HMFG2 were directly conjugated to phosphatase making the method a simple one step procedure to minimise the proportion of false positive results (Ishikawa et al., 1983) Representative samples (positive and negative controls) of the same sera were dried down using PBS (pH 7.0) alone and were compared to the sera dried down with the low pH method. It was found that the positive controls were lost when using PBS alone. Therefore the low pH has a significant effect but we do not know whether the same effect can be achieved using a different method of fixation and disruption of serum (work in progress).
Results

HMFGJ and HMFG2 assay
Several parameters have been examined and our findings (data not shown in this manuscript) were that for HMFG1 and HMFG2 and using human milk fat globule membrane (HMFG), and partially deglycosylated HMFG (Taylor-Papadimitriou, personal communication) as antigen we could detect down to 2-4ng HMFG. We used this value as the operational cut-off level, established by examining normal blood donors, the cut-off point being the mean of all samples plus 2 s.d. Although results are expressed as optical density units they can also be converted to ng 1-1 HMFG antigen.
For each assay a standard curve was performed. We found (data not shown) that the interassay and intra-assay variations were always <10% and usually between 3 and 5%.
The levels of circulating antigens detected by antibodies HMFG1 and HMFG2 are shown in Figures 1 and 2 cancer. Three patients with stage IV disease who had responded well to treatment had undetectable levels of both HMFG1 and HMFG2 antigen. It is important to state, however, that the numbers of patients with benign breast disease are too small to be able to draw firm conclusions on the incidence of raised HMFG as detected by HMFG1 and HMFG2 in this assay; in a more recent study (results not shown) of 31 patients with benign breast dise'ase we found elevated HMFG levels as detected by HMFG2 in 13 (41%). Sera were tested in 11 patients with stage I and II disease before and after surgery. In patients with completely resected tumours HMFG1 and HMFG2 levels that were elevated before surgery became undetectable by the 30th postoperative day.
The proportion of positive sera in patients with other types of benign or malignant disease is shown in Table I . These markers do not appear to discriminate between malignant and non-malignant diseases of the liver and gastrointestinal tract.
Discussion
In this study we describe a new and simple ELISA method with a low pH step to dissociate and fix serum incorporating two monoclonal antibodies HMFG1 and HMFG2 for the detection of circulating tumour associated antigens in patients with breast cancer. Other methods incorporating conventional sandwich techniques (Burchell & TaylorPapadimitriou, 1984) and using the same antibodies HMFG1 and HMFG2 have shown elevation of antigen in only 30-50% of patients with metastatic breast cancer and 5-16% of control sera. Therefore the new method described here appears to be more sensitive than the previous one. Ceriani et al. (1982) showed that a 46 Kd mol. wt human mammary epithelial antigen detected by monoclonal antibodies is elevated in the sera of patients with disseminated cancer. That 46 Kd molecule is probably distinct from the antigens detected by HMFG1 and HMFG2. Other breast epithelial antigens defined by monoclonal antibodies such as antibody MF3 (Hayes et al., 1985) , antibody F36/22 (Papsidero et al., 1984) and antibody 24-17.2 (Thomson et al., 1983) have been detected in increased amounts in the sera of patients with metastatic breast cancer. These assays developed using conventional sandwich techniques appear to be of promise in the monitoring of patients with metastatic disease. No direct comparison has been made between these assays and the new low pH method. A low pH method failed to discriminate satisfactorily between benign and malignant breast disease and has poor reproducibility (Feller et al., 1985) . The reasons for the apparent discrepancy with the previous method may be in the use of (a) different monoclonal antibodies, (b) different methodology, i.e. the new system involves a onestep procedure whilst the previous assay used a two-step procedure.
It is of interest to note that -50% of patients with stage I and II disease had elevated serum HMFG1 and HMFG2 markers prior to surgery and that 46.6% of patients in apparent clinical remission had elevated HMFG2 antigen. It remains to be determined whether this finding is of any prognostic value (Wilkinson et al., 1984) , e.g. in defining a subgroup of patients with microscopic metastases that may benefit from adjuvant therapy. HMFG2 performed better than HMFG1 in that it detected a higher percentage of patients with breast cancer.
A reliable serum assay for monitoring the response to therapy in patients with breast cancer would be an important adjunct to clinical management. Patients with metastatic breast cancer often receive chemotherapy, hormonal or other forms of therapy. It would be useful to have a noninvasive, rapid and correct determination of response to treatment that may prevent unnecessary morbidity from ineffective therapy. The detection of elevated HMFG as assayed by HMFG1 and HMFG2 low pH method would not be helpful in distinguising patients with breast cancer from those with other pathologies such as ovarian carcinoma, cholangiocarcinoma or bile duct stricture, etc. (Table I ), but could be of clinical value in monitoring the response to treatment in the majority of patients with metastatic breast cancer.
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